

Nurse Practitioner

UPDATE: New HCPCS Code to be Used When Billing for Axicabtagene Ciloleucel (brand name YESCARTA™)



Effective April 1, 2018, hospital claims for Axicabtagene Ciloleucel (brand name YESCARTA[™]) should be billed using HCPCS code Q2041. Hospitals submitting claims for YESCARTA[™] for the period December 1, 2017 through March 31, 2018 should bill using HCPCS code J3590, unlisted biologic.

New York State Medicaid covers YESCARTA[™] for members 18 years of age and older, who have a diagnosis of B-cell lymphoma, when specific criteria are met. Coverage criteria and billing guidelines are outlined in the January 2018 Medicaid Update.

If you are having problems viewing content within this newsletter, please email emednyalert@csra.com for further assistance

The Department has attempted to ensure that the information contained in these notifications is as accurate as possible. However, no e-mail transmittals or materials provided are intended to constitute legal or medical advice.



Contact Details: 1-800-343-9000 emednyalert@csra.com